RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY

<em>The article describes the clinical case of a difficult systemic juvenile arthritis refractory to traditional immunosuppressant and TNF blocker therapy. The disease was characterized by such extra-articulate manifestations as fever, lymphadenopathy, hepatolienomegaly, polyorrhymenitis, gene...

Full description

Saved in:
Bibliographic Details
Main Authors: E.I. Alexeeva (Author), S.S. Akulova (Author), E.L. Semikina (Author), T.M. Bzarova (Author), K.B. Isaeva (Author)
Format: Book
Published: "Paediatrician" Publishers LLC, 2007-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f84dbd5e53d445b3a1fca47baf7232c5
042 |a dc 
100 1 0 |a E.I. Alexeeva  |e author 
700 1 0 |a S.S. Akulova  |e author 
700 1 0 |a E.L. Semikina  |e author 
700 1 0 |a T.M. Bzarova  |e author 
700 1 0 |a K.B. Isaeva  |e author 
245 0 0 |a RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY 
260 |b "Paediatrician" Publishers LLC,   |c 2007-01-01T00:00:00Z. 
500 |a 1682-5527 
500 |a 1682-5535 
520 |a <em>The article describes the clinical case of a difficult systemic juvenile arthritis refractory to traditional immunosuppressant and TNF blocker therapy. The disease was characterized by such extra-articulate manifestations as fever, lymphadenopathy, hepatolienomegaly, polyorrhymenitis, generalized joint affection and high laboratory activity indicators (ESR, CRP). The inclusion of rituximab stimulated the remission of systemic manifestations and the joint syndrome, as well as normalized the laboratory disease activity indicators. The therapeutic effect duration was 22 weeks upon the initial infusion of rituximab. The results demonstrate that rituximab is a promising medication for treating systemic juvenile arthritis children.</em><br /><strong><em>Key words: children, treatment, rituximab, juvenile arthritis.</em></strong> 
546 |a EN 
546 |a RU 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Вопросы современной педиатрии, Vol 6, Iss 3, Pp 94-100 (2007) 
787 0 |n http://vsp.spr-journal.ru:80/jour/article/view/1232 
787 0 |n https://doaj.org/toc/1682-5527 
787 0 |n https://doaj.org/toc/1682-5535 
856 4 1 |u https://doaj.org/article/f84dbd5e53d445b3a1fca47baf7232c5  |z Connect to this object online.